PRINCETON, N.J., June 25 /PRNewswire/ -- "Congratulations President Obama on your agreement with large pharmaceutical companies to cut prescription costs for the elderly," says Mark D. Steele, president of NeoStrata Company, Inc. "We thought you should know that you have a little company in New Jersey that's done the same for psoriasis sufferers of all ages."
Mr. Steele is speaking about NeoStrata Company, Inc., and the submission of their findings from a recent clinical study announcing the significant cost-savings associated with their non-prescription, psoriasis medicine PSORENT(R) psoriasis topical solution.
Earlier this week, NeoStrata Company, Inc. submitted results for publication from an 18 week long clinical study demonstrating how psoriasis patients can save hundreds of dollars a year with their novel, non-prescription psoriasis therapy that has outperformed the leading non-steroidal prescription topical in treating the redness and scaling of psoriasis.
"In these economic times we are thrilled to be able to offer a psoriasis medicine that does not require a prescription, is significantly less expensive than most prescription drugs for psoriasis, and performs as well or better than a leading prescription medication," says Mr. Steele.
"This is not a story you hear very often, and as a small company," he explains, "we are just very excited and proud of this new psoriasis therapy and of the value it presents to patients."
NeoStrata Company, Inc. has spent the last few years developing PSORENT(R) and conducting clinical studies and after just receiving the cost savings analyses agrees the timing couldn't be better in tune with what's happening in the economy.
"As a small company," Steele explains, "we have created an affordable and preferable treatment for psoriasis that can save patients hundreds and thousands of dollars in healthcare costs, and we
|SOURCE NeoStrata Company, Inc.|
Copyright©2009 PR Newswire.
All rights reserved